1. Scrip
  2. >>Business

Tubulis Touts Transatlantic Plans As Cash Rolls In

 
• By Kevin Grogan

The German biotech is benefitting from the heat in the antibody-drug conjugate space and has concluded an upsized series B2 financing for €128m.

Tubulis management
Tubulis management team (l-r): Günter Fingerle-Rowson (CMO), Jonas Helma-Smets (CSO), Dominik Schumacher (CEO), Ingo Lehrke (CBO) and Björn Hock (CDO) • Source: Tubulis

Tubulis GmbH has yet to make it into the clinic but this has not held back the company from bringing in a sizeable amount of cash to advance its pipeline of next-generation antibody-drug conjugates (ADCs).

The Munich-headquartered group has completed an upsized and oversubscribed series B2 financing, significantly beefing up its €60m series B round in May 2022 to €128m. The round was co-led by EQT Life Sciences and Nextech Invest, with the participation from new US-based funds, Frazier Life Sciences and Deep Track Capital

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Building Up US Biopharma Manufacturing Will Require Investments In Talent

 
• By Jessica Merrill

Workforce development will be essential to meeting president Trump’s goal to return biopharma manufacturing to the US.

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.